- Home
- CNTB vs MIST Comparison
CNTB vs MIST Comparison
Compare CNTB & MIST Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | CNTB | MIST |
|---|---|---|
| Founded | 2012 | 2003 |
| Country | United States | Canada |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 135.7M | 136.9M |
| IPO Year | 2020 | 2019 |
Fundamental Metrics
Financial Performance| Metric | CNTB | MIST |
|---|---|---|
| Price | $2.44 | $1.07 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 3 | 3 |
| Target Price | ★ $8.67 | $8.00 |
| AVG Volume (30 Days) | 330.9K | ★ 1.4M |
| Earning Date | 08-13-2026 | 05-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $64,000.00 | N/A |
| Revenue This Year | N/A | $2,915.14 |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $1.23 | $1.00 |
| 52 Week High | $3.82 | $3.06 |
Technical Indicators
Market Signals| Indicator | CNTB | MIST |
|---|---|---|
| Relative Strength Index (RSI) | 59.20 | 40.23 |
| Support Level | $2.27 | $1.01 |
| Resistance Level | $2.64 | $1.42 |
| Average True Range (ATR) | 0.14 | 0.08 |
| MACD | 0.05 | -0.00 |
| Stochastic Oscillator | 72.26 | 12.12 |
Price Performance
Historical ComparisonAbout CNTB Connect Biopharma Holdings Limited
Connect Biopharma Holdings Ltd is a clinical-stage biopharmaceutical company dedicated to transforming care for asthma and chronic obstructive pulmonary disease (COPD). The company is advancing rademikibart, a next-generation antibody designed to target interleukin-4-receptor alpha. It is currently conducting clinical studies of rademikibart for the treatment of acute exacerbations of asthma and COPD. The company operates in one operating segment: treatment of respiratory diseases.
About MIST Milestone Pharmaceuticals Inc.
Milestone Pharmaceuticals Inc is a biopharmaceutical company focused on the development and commercialization of cardiovascular medicines. Its approved product CARDAMYST (etripamil) nasal spray is available in the United States and is the self-administered treatment for use by patients anywhere, anytime an attack of PSVT occurs. It operates in single segment.